Skip to main content
SpringerLink
Log in

Antiangiogene Therapie am vorderen Augenabschnitt

Wann? Was? Wofür?

Antiangiogenic therapy at the ocular surface

When, what and why?

  • Leitthema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Es gibt zahlreiche Indikationen zu einer antiangiogenen Therapie im Bereich des vorderen Augenabschnittes. Dies umfasst z. B. die visusmindernde korneale Neovaskularisation, Blutgefäße in der Hornhaut, die das Transplantatüberleben nach Keratoplastik beeinträchtigen, und die tumorassoziierte Lymphangiogenese bei Tumoren der Augenoberfläche. Mechanische Gefäßverschlüsse, wie z. B. die Feinnadelkauterisierung, und topische Anti-VEGF-Antikörper sind derzeit „off label“ die Therapie der Wahl. Basierend auf einer Literaturrecherche in PUBMED und aufbauend auf eigenen klinischen und experimentellen Daten, werden Indikationen und therapeutische Möglichkeiten sowie das Nebenwirkungsspektrum der antiangiogenen Therapie am vorderen Augenabschnitt besprochen.

Abstract

There are numerous indications for local antiangiogenic therapy at the ocular surface. These include vision-limiting corneal neovascularization, corneal blood and lymphatic vessels endangering corneal graft survival and tumor-associated lymphangiogenesis. A literature review in PubMed and own clinical and experimental data form the basis for a discussion of the indications, current therapeutic options and potential side-effects of local antiangiogenic therapy at the ocular surface.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Bachmann B, Bock F, Wiegand S et al (2008) Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 126:71–77

    Article  PubMed  Google Scholar 

  2. Bachmann BO, Luetjen-Drecoll E, Bock F et al (2009) Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol 93:1075–1080

    Article  PubMed  CAS  Google Scholar 

  3. Bachmann B, Taylor RS, Cursiefen C (2010) Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 117:1300–1305

    Article  PubMed  Google Scholar 

  4. Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545–2552

    Article  PubMed  Google Scholar 

  5. Bock F, König Y, Kruse FE et al (2008) Bevacizumab (Avastin®) eye drops inhibit corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 246:281–284

    Article  PubMed  CAS  Google Scholar 

  6. Chen L, Hamrah P, Cursiefen C et al (2004) Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) mediates dendritic cell migration to lymph nodes and induction of immunity to corneal transplants. Nat Med 10:813–815

    Article  PubMed  CAS  Google Scholar 

  7. Cursiefen C, Schlötzer-Schrehardt U, Küchle M et al (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and Podoplanin. Invest Ophthalmol Vis Sci 43:2127–2135

    PubMed  Google Scholar 

  8. Cursiefen C, Martus P, Nguyen NX et al (2002) Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty. Cornea 21:648–652

    Article  PubMed  Google Scholar 

  9. Cursiefen C, Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87:101–106

    Article  PubMed  CAS  Google Scholar 

  10. Cursiefen C, Chen L, Borges L et al (2004) Via bone marrow-derived macrophages, VEGF A mediates lymph- and hemangiogenesis in inflammatory neovascularization. Eur J Clin Invest 113:1040–1050

    CAS  Google Scholar 

  11. Cursiefen C, Maruyama K, Liu Y et al (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45:2666–2673

    Article  PubMed  Google Scholar 

  12. Cursiefen C, Chen L, Saint-Geniez M et al (2006) Nonvascular VEGFR3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 103:11405–11410

    Article  PubMed  CAS  Google Scholar 

  13. Cursiefen C, Bock F, Horn FK et al (2009) GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 116:1630–1637

    Article  PubMed  Google Scholar 

  14. Dietrich T, Bock F, Yuen D et al (2010) Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 184:535–539

    Article  PubMed  CAS  Google Scholar 

  15. Heindl LM, Hofmann T, Adler W et al (2010) Intraocular tumor-associated lymphangiogenesis: a novel prognostic factor for ciliary body melanomas with extraocular extension? Ophthalmology 117:334–342

    Article  PubMed  Google Scholar 

  16. Heindl LM, Hofmann TN, Knorr HL et al (2009) Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci 50:1988–1995

    Article  PubMed  Google Scholar 

  17. Horsley MB, Kahook MY (2010) Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 21:112–117

    Article  PubMed  Google Scholar 

  18. Hos D, Bock F, Dietrich T et al (2008) Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 49:1836–1842

    Article  PubMed  Google Scholar 

  19. Koenig Y, Bock F, Horn F et al (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375–1382

    Article  PubMed  CAS  Google Scholar 

  20. Küchle M, Cursiefen C, Nguyen NX et al (2002) Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol 240:580–584

    Article  PubMed  Google Scholar 

  21. Leippi S, Grehn F, Geerling G (2009) Antiangiogenic therapy for pterygium recurrence. Ophthalmologe 106:413–419

    Article  PubMed  CAS  Google Scholar 

  22. Nguyen NX, Seitz B, Martus P et al (2007) Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol 144:318–319

    Article  PubMed  CAS  Google Scholar 

  23. Peebo BB, Fagerholm P, Traneus-Röckert C, Lagali N (2010) Cellular-level characterization of lymph vessels in live, unlabeled corneas by in vivo confocal microscopy. Invest Ophthalmol Vis Sci 51:830–835

    Article  PubMed  Google Scholar 

  24. Regenfuss B, Bock F, Parthasarathy A, Cursiefen C (2008) Corneal (lymph)angiogenesis – from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 6:191–201

    Article  PubMed  Google Scholar 

  25. Zimmermann P, Dietrich T, Bock F et al (2009) Tumor-associated lymphangiogenesis in conjunctival malignant melanoma. Br J Ophthalmol 93:1529–1534

    Article  PubMed  CAS  Google Scholar 

  26. Bock F, König Y, Dietrich T et al (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336–344

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

  1. Augenklinik mit Poliklinik, Labor für Okuläre Angiogenese, Lymphangiogenese und Transplantatimmunologie, Universität Erlangen-Nürnberg, Universitäts-Augenklinik Erlangen, Schwabachanlage 6, 91054, Erlangen, Deutschland

    F. Bock, B. Regenfuß &  C. Cursiefen

Authors
  1. F. Bock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Regenfuß
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Cursiefen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Cursiefen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bock, F., Regenfuß, B. & Cursiefen, C. Antiangiogene Therapie am vorderen Augenabschnitt. Ophthalmologe 108, 230–236 (2011). https://doi.org/10.1007/s00347-010-2262-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-010-2262-0

Schlüsselwörter

Keywords

Search

Navigation